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Background: Asthma is a chronic inflammatory airway disease influenced by genetic and environmental factors that
affects ~300 million people worldwide, leading to ~250,000 deaths annually. Glucocorticoids (GCs) are well-known
therapeutics that are used extensively to suppress airway inflammation in asthmatics. The airway epithelium plays an
important role in the initiation and modulation of the inflammatory response. While the role of GCs in disease
management is well understood, few studies have examined the holistic effects on the airway epithelium.
Methods: Gene expression data were used to generate a co-transcriptional network, which was interrogated to
identify modules of functionally related genes. In parallel, expression data were mapped to the human protein-protein
interaction (PPI) network in order to identify modules with differentially expressed genes. A common pathways
approach was applied to highlight genes and pathways functionally relevant and significantly altered following GC
treatment.
Results: Co-transcriptional network analysis identified pathways involved in inflammatory processes in the epithelium
of asthmatics, including the Toll-like receptor (TLR) and PPAR signaling pathways. Analysis of the PPI network identified
RXRA, PPARGC1A, STAT1 and IRF9, among others genes, as differentially expressed. Common pathways analysis
highlighted TLR and PPAR signaling pathways, providing a link between general inflammatory processes and the
actions of GCs. Promoter analysis identified genes regulated by the glucocorticoid receptor (GCR) and PPAR pathways
as well as highlighted the interferon pathway as a target of GCs.
Conclusions: Network analyses identified known genes and pathways associated with inflammatory processes in the
airway epithelium of asthmatics. This workflow illustrated a hypothesis generating experimental design that integrated
multiple analysis methods to produce a weight-of-evidence based approach upon which future focused studies can be
designed. In this case, results suggested a mechanism whereby GCs repress TLR-mediated interferon production via
upregulation of the PPAR signaling pathway. These results highlight the role of interferons in asthma and their
potential as targets of future therapeutic efforts.
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Asthma is a chronic inflammatory airway disease influ-
enced by genetic and environmental factors, character-
ized by variable and recurring symptoms (wheezing,
coughing, chest tightness, shortness of breath), airflow
obstruction and bronchospasm [1]. Asthma affects ~300
million people worldwide, leading to ~250,000 deaths
annually [2]. The majority of the asthmatic population is
characterized by the development of an inflammatory re-
sponse following allergen exposure (allergic asthma).
The airway epithelium plays a critical role in allergen
sensitization in asthma. Allergens and allergen products
activate specific receptors in the surface of the epithelial
cells, including Toll-like receptors (TLRs). The activated
epithelium releases inflammatory cytokines that enhance
dendritic cell migration to lymph nodes, recruitment of
innate immune and Th2 cells to the airways, and activa-
tion of Th2 cells [3,4].
While no cure exists to date, glucocorticoids (GCs) are
commonly prescribed to control asthma symptoms [5,6].
Glucocorticoids bind to the glucocorticoid receptor
(GCR), which interacts and represses (trans-repression)
the activity of transcription factors that regulate the ex-
pression of inflammatory genes (e.g., transcription factors
AP1 and NFKB1). The activated GCR also binds to gluco-
corticoid response elements (GRE) in the DNA and pro-
motes the expression of genes with anti-inflammatory
actions (e.g., GILZ, MKP-1) [7].
Although the effects of GCs on the airway epithelium
are well known, the mechanisms mediating GCR actions
are not as well understood. A significant percentage of
the asthmatic population requires the maximum doses
of inhaled GCs and suffers the associated side effects
and a small fraction of asthmatics are resistant to GCs
[8]. Accordingly, increased insight into the molecular
mechanisms mediating GC anti-inflammatory actions
will assist in the development of therapies that minimize
resistance and side effects as well as increase our under-
standing of the disease. In addition, an understanding of
individual responses to GC treatment will assist in estab-
lishing treatment regimens tailored for personal suscep-
tibility to GCs.
We previously investigated the effects of a synthetic
GC, fluticasone propionate (Flovent), on the transcrip-
tional profile of the airway epithelium of asthmatics [9].
In that study the aim was to identify genes regulated by
GCs in the airways, and therefore the focus was on the
most significantly altered genes. We demonstrated the
GC-dependent regulation of a number of genes, includ-
ing CLCA1, POSTN, SERPINB2 and FKBP5 [9]. To gain
further insight into the processes governing the actions
of GCs in the airways, we performed an unbiased ana-
lysis to interrogate the microarray dataset from a
systems-based perspective. Our approach was primarilythat of a hypothesis generating experiment, where two
complementary network approaches were applied to mine
different aspects of cellular networks. The first method
used co-transcriptional information to characterize the
functional pathways activated in the airways. The second
method combined protein-protein interaction (PPI) net-
works with gene expression changes to identify pathways
altered following Flovent treatment. Subsequently, com-
bining results from both networks provided a weight of
evidence approach to elucidate mechanistic processes in
the action of Flovent in asthmatics. These results were fur-
ther supported by promoter enrichment analysis to
highlight a putative role of PPAR in suppressing the TLR-
mediated interferon pathway following GC treatment. The
combination of these different approaches demonstrated
how multiple analysis methods can be combined in an in
silico experiment to generate novel hypotheses. Taken to-
gether, these efforts provided a concerted investigation




Figure 1 shows an overview of the analysis workflow fol-
lowed in this study. Linear model analysis of differences
due to Flovent treatment revealed 1,492 genes that were
differentially expressed in Flovent versus placebo treated
subjects (P< 0.05, Additional file 1: Table S1). The P-
values were not corrected for multiple testing and there-
fore the list of genes is referred to as ‘RAW’. This list
included many genes with a purported role in regulation
of the immune response in asthma: interleukins (IL2,
IL27 and IL33), chemokines (CXCL1, CXCL17, CCL5
and CCL27), mucins (MUC2, MUC13 and MUCL1),
TLR7 and NOS2, among others. Functional enrichment
analysis resulted in 13 significantly enriched KEGG
pathways and 132 GO biological processes (P< 0.05)
(Additional file 2: Table S2). Additional file 3: Figure S1
shows the 10 KEGG pathways that resulted after filtering
(see Methods), including the top ones ‘Allograft rejec-
tion’, ‘Antigen processing and presentation’ and ‘Glutathi-
one metabolism’. Results for GO enrichment included:
‘antigen processing and presentation of peptide antigen
via MHC class I’, ‘antigen processing and presentation’
and ‘positive regulation of B cell proliferation’ as the top
ranking biological processes. Although the list of uncor-
rected P-values (RAW) contained many genes and path-
ways related to asthma, the results possessed a potential
high false positive rate (16,015 x 0.05 = 800 theoretical
false positives). After correction for multiple testing by
the methods of Benjamini and Hochberg [10], 115 genes
remained significantly altered with q< 0.05 (Additional
file 1: Table S1). This list of genes is referred to as ‘FDR’,
and subsequent KEGG pathway enrichment resulted in
Figure 1 Overview of the analysis workflow. This figure shows an overview of the analysis workflow followed in this study as described in the
text. From the initial microarray data (orange), three different approaches were pursued (light green). (I) Statistical analysis (II) Co-transcriptional
network analysis and (III) Interactome network analysis. Each of these paths ends with a functional analysis (blue), which was combined into a
common pathways analysis at the end of the pipeline (purple). Promoter analysis (lavender) was performed afterwards as a validation step for the
conclusions from the common pathways analysis. LM= linear models. RAW=unadjusted P-values (not corrected for multiple hypothesis testing).
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thesis’, ‘Sulfur metabolism’, ‘Primary bile acid biosynthesis’,
‘Endocytosis’ and ‘Retinol metabolism’ (Additional file 2:
Table S2 and Additional file 3: Figure S1). GO enrichment
analysis returned 123 significant terms including ‘negative
regulation of B cell activation’ and ‘B cell mediated im-
munity’ and other biological processes related to asthma.
However, only a few genes were associated with these
selected terms (1–2 genes with P~1E-03).
Analysis of the co-expression network
A co-transcriptional network was constructed from the
microarray data using the ARACNE method [11]. The net-
work was built based upon within subject differences in
transcript levels between the first sample (pre-treatment)
and the second sample (after Flovent treatment or placebo).
The inferred network contained 7,676 nodes and 49,499
edges (Additional file 3: Figure S2), and the degree distribu-
tion followed a power-law with γ=1.69 (Additional file 3:
Figure S3). The MCODE method was applied to identifyclusters of genes with similar expression profiles in the in-
ferred network [12]. This method was originally designed
to detect complexes in PPI networks, but can also be used
to detect clusters in co-transcriptional networks. MCODE
retrieved 109 modules, with module 1 (M1) being the
highest ranked (i.e., greatest connectivity in the network).
Module M1 contained 150 highly correlated genes
(average Spearman ρ=0.8074; Figure 2). Pathway analysis
resulted in 19 significantly enriched KEGG pathways
(P< 0.05, Additional file 2: Table S2), which were reduced
to 11 after pathway filtering (Additional file 3: Figure S1).
Most of the pathways enriched in M1 are directly related
to biological processes in asthma, including ‘Asthma’, ‘Cell
adhesion molecules (CAMs)’, ‘Antigen processing and
presentation’, ‘Cytokine-cytokine receptor interaction’,
‘Toll-like receptor signaling pathway’, ‘PPAR signaling path-
way’, ‘Leukocyte transendothelial migration’ and ‘Chemokine
signaling pathway’. GO enrichment analysis revealed 313
significantly enriched biological processes (P< 0.05), with
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Figure 2 MCODE module M1. Selected KEGG and GO enriched terms in the MCODE module M1. This module contains the greatest number of
genes of all modules identified via MCODE from the co-transcriptional network and has the highest MCODE score (i.e., connectivity density). A
red label indicates a gene annotated in GO (biological process) with transcription factor activity. This module contains no differentially expressed
genes identified at P< 0.05.
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the most significant term was ‘inflammatory response’
with 28 associated genes (P=1.12x10-19), including che-
mokine ligands (CXCL3, CCL4, CCL18), chemokine re-
ceptor (CCR1), complement components (C1QA, C1QB,
C1QC, C2), integrins (ITGB2), interleukins (IL1B) and
lymphocyte antigens (LY86). Other top-ranked terms
included ‘leukocyte migration’, ‘regulation of T cell activa-
tion’, ‘neutrophil chemotaxis’ and ‘regulation of interleukin
2 production’ (Additional file 2: Table S2).
The remaining modules generally contained less infor-
mation, with the exception of modules M5, M6 and
M9. Module M5 contained the greatest number of
differentially expressed genes (Additional file 3: Figure
S4, 26 differentially expressed genes at P< 0.05, and 22
genes with q< 0.05), which were both negatively and
positively correlated (absolute mean Spearman ρ=0.665;
Additional file 3: Figure S5). Only three KEGG pathways
were overrepresented, including ‘Steroid hormone biosyn-
thesis’ (Additional file 2: Table S2). GO functional analysis
revealed 40 biological processes; however, 35 of them con-
sisted of only a single gene association. Overrepresented
terms included ‘steroid metabolic process’, ‘thiamin trans-
port’, ‘positive regulation of epithelial cell proliferation’ and
‘progesterone receptor signaling pathway’ (Additional file 2:
Table S2). Module M6 contained 39 correlated genes (aver-
age Spearman ρ=0.6730; Additional file 3: Figures S5 and
S6) and appeared to be functionally related to module M1.
Some of the genes in module M6 participate in pathways
enriched in module M1, including TLR4 ('Toll-like receptor
signaling pathway'), PPARG and NFAM1 ('PPAR signalingpathway'). Module M9 had 7 correlated genes (average
Spearman ρ=0.8055) genes, including JUN, JUNB and
FOS, which are part of the AP1 transcription factor that
regulates the expression of inflammatory genes, and is a
target of the activated GCR. The enriched KEGG path-
ways that passed the filtering were ‘B-cell receptor signaling
pathway’, ‘MAPK signaling pathway’, ‘T cell receptor signal-
ing pathway’ and ‘Toll-like receptor signaling pathway’
(Additional file 3: Figure S7; Additional file 2: Table S2).
The top-ten ranked GO terms included ‘response to cyto-
kine stimulus’ and ‘SMAD protein signal transduction’
(Additional file 2: Table S2).
Analysis of the human interactome
Protein-protein interaction (PPI) networks represent the
skeleton on which signaling pathways are constructed and
can be used to identify modules of differentially expressed
genes related to the same or overlapping signaling path-
ways [13]. The human interactome was obtained from the
BioGRID database, and the BioNet software was used to
identify modules significantly enriched in differentially
expressed genes [14,15]. BioNet detected a subnetwork
containing 32 genes, including 19 upregulated and 4
downregulated (P< 0.05, 19 with q< 0.05) by Flovent
treatment (Figure 3). KEGG pathway enrichment analysis
of this module highlighted 9 significant pathways includ-
ing ‘Toll-like receptor signaling pathway’, ‘Steroid hormone
biosynthesis’, ‘PPAR signaling pathway’, ‘ErbB signaling path-
way’, and ‘Adipocytokine signaling pathway’ (Additional file
3: Figure S1; Additional file 2: Table S2). GO analysis identi-
fied 207 processes, with ‘alpha-beta T cell activation during
GeneOntology terms
KEGG Pathways
cellular response to hormone stimulus
negative regulation of mast cell cytokine production
negative regulation of T−helper 2 cell differentiation
negative regulation of T−helper 2 type immune response
regulation of cytokine production during immune response
regulation of inflammatory response
regulation of T−helper cell differentiation
response to cytokine stimulus





































Figure 3 BioNet module. BioNet module annotated with selected KEGG pathways and GO terms obtained from functional enrichment analysis.
Differentially expressed genes (P< 0.05) are indicated with a red circle (up-regulated in response to Flovent treatment) or a blue circle (down-
regulated in response to Flovent treatment). A red label indicates a gene annotated in GO (biological process) with transcription factor activity.
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Figure 4 Common pathways analysis. Analysis of common
pathways highlighted pathways present in the BioNet and selected
MCODE modules. This approach resulted in Toll-like receptor
signaling and PPAR signaling pathways as the pathways in common
with other modules. See Additional file 3: Figure S1 for a full
summary of the functional enrichment analysis.
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had a single associated gene. Some other significant bio-
logical processes not in the top rank have a direct relation
to asthma pathogenesis, including ‘negative regulation of T-
helper 2 type immune response’, ‘response to cytokine
stimulus’, ‘regulation of inflammatory response’, ‘SMAD pro-
tein signaling transduction’ and ‘cellular response to hor-
mone stimulus’ (Additional file 2: Table S2). However, these
terms also show a low number (1–2) of associated genes.
Analysis of common pathways
Networks were constructed using the two different
approaches of co-transcriptional and PPI-based analyses.
To identify cellular processes active in the airways of
asthmatics that are targeted by GC treatment, we exam-
ined common pathways found in the different modules.
We focused on common pathways between the highest
ranked MCODE module (M1) and the PPI module
(BIONET). The pathways, along with the number of
genes in each pathway, are shown in the heatmap in
Figure 4. The only common pathways were ‘Toll-like re-
ceptor signaling pathway’ and ‘PPAR signaling pathway’.
To determine whether these two pathways appeared in
common by chance, we performed a simulation with
random lists of genes of the same size as the BIONET
and M1 modules. For each random list, we performed
enrichment analysis and determined the common path-
ways. By repeating this process 1,000 times and comput-
ing the number of common pathways similar to those
detected in our analysis of the Flovent dataset, we esti-
mated the probability of observing common pathways by
chance. The simulation resulted in a probability of ran-
dom appearance as common pathways of P= 0.002 for
‘Toll-like receptor signaling pathway’. ‘PPAR signalingpathway’ did not appear as a common pathway in any of
the simulations (P= 0). These results demonstrate the
robustness of the common pathways approach.
Promoter enrichment analysis
The analysis of common pathways highlighted the TLR and
PPAR pathways as targets of GC actions. Consequently,
some of the genes regulated by these pathways should be
differentially expressed following Flovent treatment. To ex-
plore this possibility we analyzed the promoter region of
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scription factor binding sites (TFBS) associated with TLR
and PPAR pathways. The method Pscan was used to find
enriched TFBS from the JASPAR and TRANSFAC data-
bases [16]. The top enriched motifs in the JASPAR database
were IRF2 and IRF1 (P=4.1E-4 and P=4.1E-3), whereas
the top motif in the TRANSFAC database was V$IRSE_01
(P=4.1E-3) (Additional file 4: Table S4). Motifs V$IRF1
(P=0.027), V$IRF2 (P=0.041) and V$IRF7 (P=0.07) were
also significantly enriched in the TRANSFAC database.
ISRE (Interferon Stimulated Response Element) motifs are
involved in the regulation of gene expression in response to
interferon type 1 (IFNA-alpha/beta) activation [17]. IRF
motifs are the target of Interferon Regulatory Factors
(IRFs), which function as transcriptional co-activators of
interferon-regulated genes [18,19]. Interestingly, type 1
interferons (alpha and beta) are produced after activation of
TLRs (especially TLR4 and TLR7). The TFBS results also
showed enrichment of PPARG/RXRA binding motifs from
the JASPAR database (PPARG:::RXRA, P=0.0182) and the
TRANSFAC database (V$PPARG_01; P=0.084).
The enrichment motifs determined by Pscan provided
the possibility that a transcription factor could bind to the
promoter of genes. Cscan (http://159.149.109.9/cscan/)
was used in order to obtain some experimental evidence
for binding of transcription factors to the promoter region
of the list of differentially expressed genes [20]. Cscan
compiles ChIP-seq data from published experiments
assessing the binding of several transcription factors and
epigenetic markers in different cell lines for human and
mice. Results from Cscan identified GCR as the most sig-
nificantly enriched transcription factor in six different cell
lines subjected to variable doses of a glucocorticoid recep-
tor agonist (Additional file 4: Table S4). STAT1 and RXRA
binding were detected at the respective ranks of 10 and 12
(Bonferroni corrected P-values: q = 0.0009 and q= 0.0018,
respectively). Binding for PPARs or IFR9 could not be
assessed due to a lack of available experimental data.
Interferon regulatory network
Promoter analysis suggested the type 1 interferon pathway
as the most important target of GC actions. To further
validate this finding we queried the database Interferome
(http://www.interferome.org), which maintains a curated
list of known interferon-regulated genes extracted from
studies on which control and interferon-treated samples
were analyzed. We found that 20 out of 114 genes in the
FDR list (17%) have been previously identified as being
regulated by interferons (Additional file 5: Table S5). This
results in an associated probability of rejecting the null
(no enrichment) hypothesis based on the hypergeometric
distribution of P=0.0505, indicating that the FDR list is
enriched in interferon-regulated genes. Additional file 5:
Table S5 contains the number of datasets in whichregulation by a certain type of interferon was found. Type
1 interferons regulated 17 out of 20 genes in a total of 72
datasets, whereas type 2 interferons were the only source
of regulation for three genes in a total of 3 datasets. Taken
together, these results suggest that GCs target the type 1
interferon pathway in the epithelium of asthmatics.
Discussion
Classical statistical and functional enrichment analysis of
the Flovent/placebo dataset provided little insight into
the biological processes associated with the treated asth-
matics. Results from the uncorrected tests contained
many genes known to be associated with asthma, and
some enriched pathways and GO terms linked these
genes to inflammatory responses and metabolism of
GCs. However, the high number of potential false posi-
tives hampered the results and correction for multiple
testing eliminated most of these genes from the final list.
Genes selected after multiple testing correction (FDR)
identified the SERPINB2 and FKBP5 genes, which were
previously validated [9]. However, the FDR approach
failed to identify CLCA1, another gene experimentally
confirmed [9], although it was significantly altered based
on uncorrected P-values. This effect could partially be
attributed to the reduced statistical power associated
with the use of multiple testing correction methods
compared to the uncorrected analysis [21]. It has been
well demonstrated that the excessive penalty imposed on
P-values following FDR adjustment increases the num-
ber of false negatives [22]. On the other hand, POSTN,
which was also experimentally validated, had a P> 0.05
and therefore was not differentially expressed in our
analysis. This comparison highlights some of the limita-
tions associated with statistical analyses that rely on a
single source of evidence to derive conclusions on bio-
logical function, and argues for the need for integrative
approaches to data analysis.
Network analysis offers some advantages over classical
analysis by being able to incorporate additional informa-
tion from multiple sources [21,23,24]. We applied a
weight-of-evidence approach by using multiple methods
that mine different aspects of the cellular processes,
which converged to ‘Toll-like receptor signaling path-
way’ and ‘PPAR signaling pathway’ as the most relevant
pathways related to GC treatment (Figure 4). Toll-like
receptors (TLRs) regulate inflammatory responses by
inducing the expression of inflammatory cytokines upon
binding of viral or bacterial proteins and mediate the
signaling pathways that regulate innate and Th2
responses in the epithelium [3,25,26]. Toll-like receptors,
including TLR4 (found in module M6) and TLR7 (found
in module M1) mediate the production of interferons
alpha and beta (type 1 interferons) [27]. This important
link between TLR and the interferon 1 pathway, not
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by the promoter enrichment analysis.
Type 1 interferons act in an autocrine or paracrine
manner and bind to interferon-alpha receptors in the
membrane. This activates the Janus kinase and signal
transducers and activators of transcription (JAK/STAT)
pathway, which regulates the expression of inflammatory
genes [17]. Phosphorylation of STAT1 by JAK1 activates
STAT1, which forms a heterodimer with STAT2 and
recruits IRF9 to form the IFN-stimulated gene factor 3
(ISGF3) transcriptional complex [18,19]. The analysis of
the human interactome identified STAT1 and IRF9,
which are downregulated (P< 0.05) by Flovent (Figure 3).
In addition, promoter analysis identified ISRE as the top
enriched transcription factor motif in the list of differen-
tially expressed genes (q< 0.05). This suggests a mech-
anism in which GCs regulate the type 1 interferon
pathway by downregulating the proteins involved in
interferon signal transduction. However, although both
STAT1 and IRF9 are suggested as differentially expressed
(P< 0.05) and exhibited correlated expression profiles
(r = 0.771, P= 3.7E-07), their correlation with treatment
is less clear (Figure 5). Interestingly, GCs are known to
regulate the type 1 interferon pathway by suppressing
the phosphorylation of STAT1 [28], providing an alterna-
tive mechanism of regulation.
STAT1 phosphorylation also mediates the transduction
of type 2 interferon (IFN-gamma) signaling by binding
to gamma-activated sequence (GAS) elements as an
homodimer. Therefore, it is possible that downregula-
tion of STAT1 and inhibition of phosphorylation of the
protein represses type 2 interferon signaling. Indeed,
GCs are known to inhibit IFN-gamma signaling by
downregulating STAT1 mRNA and protein expression in
PBMCs [29]. Gene expression for type 2 interferon and
its receptor (IFN-gamma receptor, IFNGR) were found
in the microarray dataset after filtering non-expressed
genes (not shown). However, promoter analysis only









































































Figure 5 STAT1 and IRF9 expression profiles. STAT1 and IRF9 show cor
treatment.motif for the ISGF3 transcriptional complex, GAS ele-
ments were not detected. In addition, interrogation of
the interferome database resulted in a list of interferon-
regulated genes that were, in the majority of datasets
assayed, regulated by type 1 interferons. Consequently,
although a role of type 2 interferons cannot be excluded,
our findings suggest that type 1 interferons are the target
of GCs in the epithelium of asthmatics.
Peroxisome proliferator-activated receptors (PPAR) are
lipid-activated transcription factors that regulate the ex-
pression of target genes [30]. PPAR-alpha and -gamma
modulate allergic inflammation, and agonists are able to
reduce levels of inflammatory cytokines [31,32]. PPARs
exert their activity by forming a heterodimer with the
retinoid receptor RXRA, which then binds to co-activator
proteins, including PPARGC1A (PGC-1), to regulate gene
expression. Transcriptional co-activators amplify the tran-
scription of nuclear receptor regulated target genes [33].
In particular, PPARGC1A can recruit other co-activator
proteins with histone acetyltransferase (HAT) activity that
open up the chromatin and enhance the expression of tar-
get genes [34]. Consequently, an increase in the expres-
sion of RXRA and PPARGC1A co-activators can intensify
the activity of the PPAR pathway, resulting in an increased
repression of STAT1 phosphorylation. Both RXRA and
PPARGC1A are present in the BioNet module and are
upregulated by Flovent (Figure 3). Promoter analysis also
resulted in an enrichment of genes with PPARG:RXRA
motifs (P~0.01). This suggests that GCs modulates the
activity of the PPAR pathway by upregulating co-
transcriptional activators. Supporting this evidence, the
expression profiles for RXRA and PPARGC1A are corre-
lated (r = 0.4078, P=0.022) and show a trend of higher
levels in Flovent-treated patients (Additional file 3: Figure
S8).
Our results link GCs to type 1 interferon and PPAR
pathways. There is previous evidence that connects PPARs
to interferons, providing an interesting mechanism integrat-
































































related expression profiles and are downregulated following Flovent
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rat glia [35]. However, in our study promoter analysis iden-
tified PPARG, but not PPARA (P~0.2), motifs enriched in
the list of differentially expressed genes. This lack of signifi-
cance could be explained by the fact that PPARA motifs
are missing in the JASPAR database, which retrieved higher
significant results for the complex PPARG:RXRA transcrip-
tion factor motif. In addition, our search strategy looked for
motifs in the 1 kb region upstream of the transcription start
site, whereas some transcription factors can bind to more
distal locations. Alternatively, as our data suggest, GC ac-
tion on type 1 interferons may be mediated via a PPAR-
gamma-dependent process. For example, it has been shown
that PPAR-gamma can repress the type 1 interferon path-
way by downregulating the production of INF-beta upon
TLR4 activation [36]. Treatment with the PPAR-gamma
agonist troglitazone and challenge with LPS and poly(I:C)
impaired IRF3 binding to the IFN-beta-promoter. Downre-
gulation of IFN-beta prevented activation of the IFN-beta
receptor and subsequent STAT1 phosphorylation and ISRE
activation [36]. However, in our dataset type 1 interferons
were present, but not differentially expressed (average
P~0.58 for type 1 interferon genes in the microarray).
Interestingly, activation of the PPAR-gamma pathway was
previously found to downregulate the expression of IFN-
gamma activated genes [37]. These findings highlight the
complex nature of PPAR-mediated interferon regulation,
which can affect different pathways (type 1 vs. type 2) at
multiple regulatory points.
Our findings provide a link between interferon, PPARs
and GCs that suggests a model similar to that presented in
Figure 6. In this model, allergens activate the TLR signaling,
which in turn activates the production of type 1 interferons.
The alpha/beta interferons then bind to interferon recep-
tors (IFNAR1/2) that stimulate the phosphorylation of
STAT1 and promote the expression of genes with a num-
ber of inflammatory effects. Treatment with GCs upregu-
lates PPARGC1A and RXRA coactivator molecules, which
consequently enhance the PPAR pathway. Activation of the
PPAR pathway inhibits phosphorylation of STAT1 and
therefore inhibits the interferon pathway. In addition, GCs
may repress the interferon pathway by downregulation of
STAT1 and IRF9 transcription factors. In this model, PPARs
could be potential mediators of the anti-inflammatory
actions of GCs. Both PPAR-alpha and -gamma inhibit air-
way inflammation in a murine module of asthma [32]. The
use of PPAR-gamma agonists has been shown to evidence
improvements in lung function of smokers with asthma
(improved FEV1; forced expiratory volume in 1 sec), who
had previously demonstrated a reduced response to GC
treatment [38]. While the mechanism for the observed
improvements in lung function was unclear, it was postu-
lated that PPAR-gamma could independently modulate a
set of inflammatory genes relative to GCs [39].A link between GCs and the interferon pathways
has been previously reported [5,40-42], and interfer-
ons are known to affect symptoms in asthmatics [43-
46]. Interferon-alpha has been associated with severe
exacerbation of asthma symptoms [43], which provides a
simple mechanistic interpretation of the beneficial effects
of GC-mediated repression of the interferon pathway. On
the other hand, low doses of interferon-alpha have been
associated with therapeutic effects in GC-resistant
patients [44-46]. It is unclear if these disparate responses
are due to differences in interferon dose or different pa-
tient phenotype. This clearly highlights the inherent com-
plexity of the underlying regulatory networks and the
need of further studies investigating the mechanisms of
GCs and their relation with the interferon pathway.
Conclusions
Multifactorial diseases such as asthma challenge our ability
to identify distinct mechanisms involved in disease etiology
and pathology. The advent of high-throughput approaches
has increased the amount of information that can be
extracted from a sample set, but linking together disparate
datasets remains an elusive goal. Technologies that summa-
rize the principal disease processes affected (e.g., functional
enrichment analysis) assist in characterizing the primary
functional features, but often fail to suggest detailed infor-
mation of disease and treatment action. Accordingly, ap-
proaches that incorporate information regarding multiple
biological aspects from disparate sources can stimulate the
generation of hypotheses that will uncover novel mechan-
isms. Given that asthma is a heterogeneous inflammatory
condition, it is of interest to examine for distinct molecular
phenotypes. For example, it has been shown that respon-
siveness to inhaled GCs correlates with the degree of Th2
inflammation. It is possible that distinct subgroups of asth-
matics exist with specific shifts in PPAR/TLR pathways that
correlate with GC responsiveness or other molecular phe-
notypes, such as the IL-13 related Th2 sub-phenotypes pre-
viously described for the current data set [47,48]. Further
investigations to investigate sub-phenotypical responses in
the PPAR/TLR pathways are thus warranted.
With the workflow presented herein, we were able to
identify specific pathways as being targets of GCs in the
epithelium of asthmatics. Results highlighted the promin-
ent role of interferons in mediating inflammatory processes
in asthmatics, and further supported the finding that GCs
mediate their activities by repressing the interferon path-
way. We found that this repression may be mediated by
GC-dependent upregulation of the PPAR pathway. A po-
tential mechanism of direct repression of the interferon
pathway by downregulation of key transcription factors is
also suggested. If confirmed, these findings will be poten-
tially valuable in the design of new therapies tailored for
the GC-resistant asthmatic sub-population.
AB
Figure 6 Model of glucocorticoid (GC) actions in the airways epithelium. Simplified (A) and detailed (B) model of PPAR-mediated anti-
inflammatory actions of GC in lung epithelial cells. Following activation by allergens, TLRs activate the type 1 interferon pathway. Interferons
induce the expression of inflammatory genes mediated by phosphorylated STAT1 and IRF9 transcription factors. GC treatment represses the
interferon pathway via two potential mechanisms. First, upregulation (orange boxes) of RXRA and PPARGC1A enhances the activity of the PPAR
pathway, which inhibits STAT1 phosphorylation, repressing interferon signaling. Secondly, down-regulation (blue boxes) of STAT1 and IRF9, reduces
the amount of the transcriptional complex responsible for interferon-regulated gene expression. Clear arrowheads indicate phosphorylation. Solid
arrowheads indicate activation. A dashed line represents transcriptional regulation (arrow: activation; T: repression).
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Microarray data acquisition and preprocessing
The microarray data set was published previously, and
is available in the GEO database (accession number
GSE4302) [9]. The dataset consisted of 64 Affymetrix
HGU133plus2 arrays measuring expression profiles from
airway epithelial brush biopsies obtained from 32 asth-
matics in a randomized, blinded parallel group study design
with sampling at baseline levels and after 1 week treatment
with either placebo or fluticasone propionate (Flovent). Ob-
servation 55 was identified as an outlier due to poor tech-
nical quality of the microarray data, and was excluded from
all analyses. Custom CDFs (Chip Description File) from the
BrainArray Project were used to map the array probes to
17,788 probe sets corresponding to individual Entrez Gene
entries [49]. Arrays were preprocessed with the RMA
method from the Bioconductor package affy [50,51]. Non-
expressed genes were eliminated on the basis of XIST
expression, which is not expressed in males [52]. The distri-
bution of intensities for XIST in male and females was com-
puted (Additional file 3: Figure S9), and the background
threshold estimated as the median value of the distribution
in males (log2 median intensity =5.32). Genes wereeliminated when the intensity in all arrays was below that
of the determined threshold value. The resulting microarray
data contained 16,015 remaining genes. Baseline correction
was performed by computing the log difference of the in-
tensity values from baseline and post-treated arrays prior to
statistical analysis.
Statistical analysis
Statistical analysis was performed with the Bioconductor
package limma [53]. A linear model was constructed in-
cluding drug (i.e., Flovent or placebo), sex and age in the
design matrix. P values associated with the comparison
Flovent vs. placebo were computed. Multiple testing cor-
rection was applied using the method of Benjamini and
Hochberg [10].
Co-transcriptional network
A co-transcriptional network was constructed from the
microarray data using the ARACNE method, which uses
mutual information (MI) to test statistical dependency be-
tween expression profiles [11]. Due to concerns about the
effects of low sample numbers in combination with the in-
herent biological variability upon the statistical dependency,
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treated) were included in the co-transcriptional network in-
ference. To reduce the inter-individual variance from the
gene expression profiles, expression values were normalized
to the baseline values for each individual (i.e., samples col-
lected prior to initialization of treatment regimen). Mutual
information was computed using a Gaussian Kernel esti-
mate. Two critical parameters for the ARACNE method
are the kernel width and the MI threshold, which are nor-
mally estimated using precomputed calibration curves.
However, for this project, custom calibration curves were
constructed using the MATLAB scripts provided in the
original publication [11]. A calibration curve for kernel
width was generated (Additional file 3: Figure S10A) and
the optimal kernel width was determined to be 0.2179931,
which is 5.3% lower than that estimated by ARACNE
(0.230167). The calibration curve for the MI threshold
was computed (Additional file 3: Figure S10B) and used
during network reconstruction. Next, the optimal P-value
cutoff for network reconstruction was determined by
computing networks at different P-values over a suffi-
ciently wide range. For each network, the number of
nodes, edges and degree distribution was computed
(Additional file 3: Figure S11A), and a P-value of 1.0E-8
was chosen, which resulted in a power law degree distri-
bution for the network (Additional file 3: Figures S3 and
S11B). Finally, in order to assess the effect of sample
ordering upon correlation estimations (MI), a boot-
strapped network was computed by setting 100 cycles and
the consensus network was calculated with a Bonferroni
corrected q< 0.001 [54].
Protein-protein interaction network
Information about protein-protein interactions (PPI) was
obtained from the BioGRID database [15], which contains
experimentally validated data from a range of high-
throughput and low-throughput techniques. The database
version 3.1.70 contained information on 9,935 genes,
which formed a network with 50,531 edges. This network
contained multiple edges joining the same pair of genes
(i.e., the interaction has several sources of evidence), and
therefore for module detection the network was simplified
by using the simplify function in the R package igraph
(http://igraph.sourceforge.net), to reduce the number of
edges per pair of genes to one. The resulting simplified
network contained 33,282 edges.
Module detection
For the co-transcriptional network, detection of clusters
of densely connected nodes was performed using the
MCODE plugin for the Cytoscape software with default
parameters [55]. For the BioGRID PPI network, module
detection was performed using the Bioconductor pack-
age BioNet [14], which enables the determination of anexact solution to the problem of finding connected sub-
graphs with low P-values. A Binomial Uniform Mixture
(BUM) model was fitted to the distribution of P-values,
and scores were derived for each network node at a
given FDR (q = 0.05). Finally, these scores were used to
detect modules using the exact Heinz method [56].
Functional enrichment analysis
Functional enrichment analysis for KEGG pathways and
Gene Ontology (GO) Biological Process (BP) terms
(downloaded on 2010/09/07 and 2010/09/04 respectively)
was performed using a hypergeometric test as implemen-
ted in the Bioconductor package GOstats [57]. For GO, a
conditional test that considers the dependence structure
of the GO terms was performed [58]. The lists of probe
sets from the statistical analysis and modules from the co-
transcriptional network were converted into lists of Entrez
Gene identifiers prior to enrichment analysis. Enrichment
results were considered significant at P< 0.05.
KEGG pathways were restricted to those involved in bio-
logical processes. Consequently, disease pathways were dis-
carded (except the KEGG pathway ‘Asthma’). In addition,
pathways that were supported with less than two genes in
any module or list of differentially expressed genes were
discarded. The final list of KEGG pathways was used to fil-
ter modules in the co-transcriptional network. Modules
that did not contain any genes annotated in the KEGG
pathways that passed the filtering were discarded. Pathways
were grouped using a hierarchical clustering with Pearson
correlation as a distance measure, and the gene counts dis-
played as a heatmap.
Common pathways analysis
To link the results from the co-transcriptional and PPI
network analyses, common pathways were selected when
present simultaneously in the BIONET module and the
MCODE module M1 from the co-transcriptional network.
To assess the possibility that the selected common path-
ways appeared by chance in our dataset, we performed
simulations with random lists of genes. First, background
lists of genes were generated by randomly selecting genes
from the total number of genes (universe) used for enrich-
ment analysis. The number of genes in each simulated list
was the same as the target list (i.e., the same number of
genes as found in the BIONET and MCODE module M1).
A KEGG enrichment analysis was then performed for
each list as described above, and the common pathways
were computed. Finally, the common pathways in the
simulation were compared to those obtained with the real
dataset and the number of positive hits n recorded. This
process was repeated N=1000 times and the probability
of a pathway appearing by chance was computed as the
number of times it appeared as common in the simulated
datasets divided by the number of simulations (P=n / N).
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Promoter enrichment analysis was performed to iden-
tify transcription factor binding motifs enriched in the
promoter regions of sets of genes by using the soft-
ware Pscan [16]. Entrez Gene identifiers were con-
verted into REFSEQ ids and these were loaded into
the Pscan web server. JASPAR and TRANSFAC data-
bases of transcription factor motifs were selected to
analyze the region from −950 to +50 bases relative to
the transcription start site (TSS). Transcription factor
binding assessment was performed to identify experi-
mental evidence (based on published ChIP-seq data) of
binding of transcription factors to the promoter region
of the differentially expressed genes. Entrez Gene iden-
tifiers were converted into REFSEQ ids, which were
loaded into the Cscan web server [20]. A region be-
tween −1,000 upstream of the TSS and the transcribed
region of the gene was selected to identify transcrip-
tion factor binding events.
Interferon regulated genes
The database Interferome (http://www.interferome.org)
was used to identify interferon target genes [59]. This
database catalogs genes regulated in microarray and
other experiments where comparisons between control
and interferon treated samples were performed. Entrez
Gene identifiers were converted into EnsEMBL gene
identifiers and loaded into the Interferome web server.
Enrichment of interferon-regulated genes was computed
using the hypergeometric test implemented in the R
software. The parameters were set with 20,900 as total
number of genes in the human genome (based on data
from the EnsEMBL database release 64) and 2,000 as the
number of interferon-regulated genes (as stated in the
Interferome web site). Since the number of interferon-
regulated genes is an estimate, the enrichment calcula-
tion is only approximate.
Additional files
Additional file 1: Table S1. Stat_analysis_results.xlsx (Microsoft Excel
XLSX) Lists of genes found significantly changed in the statistical analysis.
Additional file 2: Table S2. Func_enrich_results.xlsx (Microsoft Excel
XLSX) Results for KEGG pathways and GO terms functional enrichment
analysis.
Additional file 3: Supp_material.pdf (Adobe PDF) Supplementary
information and figures for the main manuscript [11,52,54].
Additional file 4: Table S4. Promoter analysis.xlsx (Microsoft Excel
XLSX) Results from Pscan promoter enrichment analysis with JASPAR and
TRANSFAC, and results from Cscan ChIP-seq analysis.
Additional file 5: Table S5. Interferon_regulated_genes.xlsx (Microsoft
Excel XLSX) List of known interferon-regulated genes from the FDR set.
Competing interest
The authors declare no competing interests.Authors’ contributions
DD helped to design the study, performed the analyses and wrote the
manuscript. SG provided computational resources for network generation
and assisted in development of the methods for pathway enrichment
analysis. JVF helped design the study and provided the initial microarray
dataset. DJE helped design the study, provided the initial microarray dataset,
and critically revised the manuscript. PGW helped design the study, provided
the initial microarray dataset, provided clinical input, and helped critically
revise the manuscript. ÅMW conceived of the study and assisted in writing
the manuscript. CEW conceived of the study, assisted in the analyses, and
assisted in writing the manuscript. All authors have read and approved the
final manuscript.Acknowledgements
This work was supported in part by the Center for Allergy Research, the
Bernard Osher Initiative for Research on Severe Asthma, the Swedish Heart-
Lung Foundation, the Swedish Foundation for Strategic Research, a
VINNOVA VINN-MER International Grant, and VINNOVA and JSPS under the
Sweden-Japan Research Cooperative Program. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Author details
1Bioinformatics Center, Institute for Chemical Research, Kyoto University, Uji,
Kyoto 611-0011, Japan. 2Division of Pulmonary and Critical Care Medicine,
Department of Medicine, University of California San Francisco, San
Francisco, CA, USA. 3Lung Biology Center, University of California San
Francisco, San Francisco, CA, USA. 4Cardiovascular Research Institute,
University of California San Francisco, San Francisco, CA, USA. 5Respiratory
Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm,
Sweden. 6Department of Medical Biochemistry and Biophysics, Division of
Physiological Chemistry II, Karolinska Institutet, Stockholm, Sweden.
7Laboratory of Bioinformatics and Genomics, World Premier International
Immunology Frontier Research Center, Osaka University, Osaka 565-0871,
Japan.
Received: 10 February 2012 Accepted: 21 May 2012
Published: 19 June 2012References
1. Fanta CH: Asthma. N Eng J Med 2009, 360(10):1002–1014.
2. Global Initiative for Asthma (GINA): Global strategy for asthma management
and prevention. Bethesda (MD): Global Initiative for Asthma (GINA); 2010.
3. Bulek K, Swaidani S, Aronica M, Li X: Epithelium: the interplay between
innate and Th2 immunity. Immunol Cell Biol 2010, 88(3):257–268.
4. Hammad H, Lambrecht BN: Dendritic cells and epithelial cells: linking
innate and adaptive immunity in asthma. Nat Rev Immunol 2008,
8(3):193–204.
5. Stellato C: Glucocorticoid actions on airway epithelial responses in
immunity: functional outcomes and molecular targets. J Allergy Clin
Immunol 2007, 120(6):1247–1263. quiz 1264–1245.
6. Barnes PJ: Inhaled glucocorticoids for asthma. N Eng J Med 1995, 332
(13):868–875.
7. Barnes PJ: Glucocorticosteroids: current and future directions. Br J
Pharmacol 2010, 120(2-3):76–85.
8. Barnes PJ, Adcock IM: Glucocorticoid resistance in inflammatory diseases.
Lancet 2009, 373(9678):1905–1917.
9. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S,
Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, et al: Genome-wide profiling
identifies epithelial cell genes associated with asthma and with
treatment response to corticosteroids. Proc Natl Acad Sci USA 2007,
104(40):15858–15863.
10. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical
and Powerful Approach to Multiple Testing. Journal of the Royal Statistical
Society Series B (Methodological) 1995, 57:289–300.
11. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R,
Califano A: ARACNE: an algorithm for the reconstruction of gene
regulatory networks in a mammalian cellular context. BMC Bioinformatics
2006, 7(1):S7.
Diez et al. BMC Medical Genomics 2012, 5:27 Page 12 of 13
http://www.biomedcentral.com/1755-8794/5/2712. Shi Z, Derow CK, Zhang B: Co-expression module analysis reveals
biological processes, genomic gain, and regulatory mechanisms
associated with breast cancer progression. BMC Syst Biol 2010, 4:74.
13. Ideker T, Ozier O, Schwikowski B, Siegel AF: Discovering regulatory and
signalling circuits in molecular interaction networks. Bioinformatics 2002,
18(Suppl 1):S233–S240.
14. Beisser D, Klau GW, Dandekar T, Muller T, Dittrich MT: BioNet: an R-Package
for the functional analysis of biological networks. Bioinformatics 2010,
26(8):1129–1130.
15. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M: BioGRID:
a general repository for interaction datasets. Nucleic Acids Res 2006,
34:D535–D539. Database issue.
16. Zambelli F, Pesole G, Pavesi G: Pscan: finding over-represented
transcription factor binding site motifs in sequences from co-regulated
or co-expressed genes. Nucleic Acids Res 2009, 37:W247–W252. Web Server
issue.
17. Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins.
Science 1994, 264(5164):1415–1421.
18. Lawrence T, Natoli G: Transcriptional regulation of macrophage
polarization: enabling diversity with identity. Nat Rev Immunol 2011,
11(11):750–761.
19. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A,
Melero I: Direct effects of type I interferons on cells of the immune
system. Clin Cancer Res 2011, 17(9):2619–2627.
20. Zambelli F, Pavesi G: Cscan: Finding Common Regulators In A Set Of
Genes Using Genome-Wide Chip-Seq Data. In Next Generation Sequencing
Workshop. Italy: Bari; 2011. October 12–14 2011.
21. Diez D, Wheelock AM, Goto S, Haeggstrom JZ, Paulsson-Berne G, Hansson
GK, Hedin U, Gabrielsen A, Wheelock CE: The use of network analyses for
elucidating mechanisms in cardiovascular disease. Mol Biosyst 2010, 6
(2):289–304.
22. Ioannidis JP, Tarone R, McLaughlin JK: The false-positive to false-negative
ratio in epidemiologic studies. Epidemiology 2011, 22(4):450–456.
23. Barabasi AL, Gulbahce N, Loscalzo J: Network medicine: a network-based
approach to human disease. Nat Rev Genet 2011, 12(1):56–68.
24. Lee DS, Park J, Kay KA, Christakis NA, Oltvai ZN, Barabasi AL: The
implications of human metabolic network topology for disease
comorbidity. Proc Natl Acad Sci USA 2008, 105(29):9880–9885.
25. Uematsu S, Akira S: Toll-like receptors and innate immunity. J Mol Med
(Berl) 2006, 84(9):712–725.
26. Lambrecht BN, Hammad H: The role of dendritic and epithelial cells as
master regulators of allergic airway inflammation. Lancet 2010,
376(9743):835–843.
27. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN: TLR-dependent
and TLR-independent pathways of type I interferon induction in
systemic autoimmunity. Nat Med 2007, 13(5):543–551.
28. Bhattacharyya S, Zhao Y, Kay TW, Muglia LJ: Glucocorticoids target
suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to
regulate Toll-like receptor-induced STAT1 activation. Proc Natl Acad Sci
USA 2011, 108(23):9554–9559.
29. Hu X, Li WP, Meng C, Ivashkiv LB: Inhibition of IFN-gamma signaling by
glucocorticoids. J Immunol 2003, 170(9):4833–4839.
30. Kelly DP: The pleiotropic nature of the vascular PPAR gene regulatory
pathway. Circ Res 2001, 89(11):935–937.
31. Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, Kim JS, Lee MK, Lee YC:
PPAR-gamma modulates allergic inflammation through up-regulation of
PTEN. FASEB J 2005, 19(8):1033–1035.
32. Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P: PPAR-alpha
and -gamma but not -delta agonists inhibit airway inflammation in a
murine model of asthma: in vitro evidence for an NF-kappaB-independent
effect. Br J Pharmacol 2003, 139(1):163–171.
33. Wolf IM, Heitzer MD, Grubisha M, DeFranco DB: Coactivators and nuclear
receptor transactivation. J Cell Biochem 2008, 104(5):1580–1586.
34. Liu C, Lin JD: PGC-1 coactivators in the control of energy metabolism.
Acta Biochim Biophys Sin 2011, 43(4):248–257.
35. Lee JH, Joe EH, Jou I: PPAR-alpha activators suppress STAT1 inflammatory
signaling in lipopolysaccharide-activated rat glia. Neuroreport 2005,
16(8):829–833.
36. Zhao W, Wang L, Zhang M, Wang P, Zhang L, Yuan C, Qi J, Qiao Y, Kuo PC, Gao
C: Peroxisome proliferator-activated receptor gamma negatively regulatesIFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated
macrophages by preventing interferon regulatory factor 3 binding to the
IFN-beta promoter. J Biol Chem 2011, 286(7):5519–5528.
37. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P,
Plutzky J, Luster AD: Peroxisome proliferator-activated receptor-gamma
activators inhibit IFN-gamma-induced expression of the T cell-active CXC
chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol
2000, 164(12):6503–6508.
38. Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, Lafferty J,
Chaudhuri R, Braganza G, Bareille P, et al: Bronchodilatory effect of the
PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin
Pharmacol Ther 2009, 86(1):49–53.
39. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A,
Subramaniam S, David M, Rosenfeld MG, et al: Molecular determinants of
crosstalk between nuclear receptors and toll-like receptors. Cell 2005,
122(5):707–721.
40. Stojadinovic O, Lee B, Vouthounis C, Vukelic S, Pastar I, Blumenberg M, Brem
H, Tomic-Canic M: Novel genomic effects of glucocorticoids in epidermal
keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and
wound healing along with promotion of terminal differentiation. J Biol
Chem 2007, 282(6):4021–4034.
41. Tliba O, Cidlowski JA, Amrani Y: CD38 expression is insensitive to steroid action
in cells treated with tumor necrosis factor-alpha and interferon-gamma by a
mechanism involving the up-regulation of the glucocorticoid receptor beta
isoform. Mol Pharmacol 2006, 69(2):588–596.
42. Tliba O, Damera G, Banerjee A, Gu S, Baidouri H, Keslacy S, Amrani Y:
Cytokines induce an early steroid resistance in airway smooth muscle
cells: novel role of interferon regulatory factor-1. Am J Respir Cell Mol Biol
2008, 38(4):463–472.
43. Bini EJ, Weinshel EH: Severe exacerbation of asthma: a new side effect of
interferon-alpha in patients with asthma and chronic hepatitis C.
Mayo Clin Proc 1999, 74(4):367–370.
44. Gratzl S, Palca A, Schmitz M, Simon HU: Treatment with IFN-alpha in
corticosteroid-unresponsive asthma. J Allergy Clin Immunol 2000,
105(5):1035–1036.
45. Mouthon L, Guillevin L: Interferon-alpha in corticosteroid-resistant asthma
and Churg-Strauss syndrome. Allergy 2003, 58(12):1244–1246.
46. Simon HU, Seelbach H, Ehmann R, Schmitz M: Clinical and
immunological effects of low-dose IFN-alpha treatment in patients
with corticosteroid-resistant asthma. Allergy 2003, 58(12):1250–1255.
47. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL,
Arron JR, Fahy JV: T-helper type 2-driven inflammation defines major
subphenotypes of asthma. Am J Respir Crit Care Med 2009, 180(5):388–395.
48. Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, Fedorowicz
G, Modrusan Z, Fahy JV, Woodruff PG, et al: Gene expression patterns of
Th2 inflammation and intercellular communication in asthmatic airways.
J Immunol 2011, 186(3):1861–1869.
49. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers
RM, Speed TP, Akil H, et al: Evolving gene/transcript definitions
significantly alter the interpretation of GeneChip data. Nucleic Acids Res
2005, 33(20):e175.
50. Gautier L, Cope L, Bolstad BM, Irizarry RA: affy–analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 2004, 20(3):307–315.
51. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, et al: Bioconductor: open software development
for computational biology and bioinformatics. Genome Biol 2004,
5(10):R80.
52. Brown CJ, Hendrich BD, Rupert JL, Lafreniere RG, Xing Y, Lawrence J, Willard
HF: The human XIST gene: analysis of a 17 kb inactive X-specific RNA
that contains conserved repeats and is highly localized within the
nucleus. Cell 1992, 71(3):527–542.
53. Smyth GK: Limma: linear models for microarray data. In Bioinformatics and
Computational Biology Solutions using R and Bioconductor. Edited by Gentleman
R, Carey V, Dudoit S, Irizarry R, Huber W. New York: Springer; 2005:397–420.
54. Bonferroni CE: Il calcolo delle assicurazioni su gruppi di teste. Studi in
Onore del Professore Salvatore Ortu Carboni 1935, :13–60.
55. Bader GD, Hogue CW: An automated method for finding molecular
complexes in large protein interaction networks. BMC Bioinformatics 2003, 4:2.
56. Dittrich MT, Klau GW, Rosenwald A, Dandekar T, Muller T: Identifying
functional modules in protein-protein interaction networks: an
integrated exact approach. Bioinformatics 2008, 24(13):i223–i231.
Diez et al. BMC Medical Genomics 2012, 5:27 Page 13 of 13
http://www.biomedcentral.com/1755-8794/5/2757. Falcon S, Gentleman R: Using GOstats to test gene lists for GO term
association. Bioinformatics 2007, 23(2):257–258.
58. Alexa A, Rahnenfuhrer J, Lengauer T: Improved scoring of functional
groups from gene expression data by decorrelating GO graph structure.
Bioinformatics 2006, 22(13):1600–1607.
59. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ: INTERFEROME: the database of
interferon regulated genes. Nucleic Acids Res 2009, 37:D852–D857. Database
issue.
doi:10.1186/1755-8794-5-27
Cite this article as: Diez et al.: Network analysis identifies a putative role
for the PPAR and type 1 interferon pathways in glucocorticoid actions
in asthmatics. BMC Medical Genomics 2012 5:27.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
